Comparative Pharmacology
Head-to-head clinical analysis: ADVIL versus SULINDAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVIL versus SULINDAC.
ADVIL vs SULINDAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby reducing pain, fever, and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis. Prodrug converted to active sulfide metabolite which inhibits COX enzymes.
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day (OTC). For prescription: 400-800 mg orally 3-4 times daily; maximum 3200 mg/day.
150-200 mg orally twice daily, with maximum daily dose 400 mg.
None Documented
None Documented
2-4 hours (terminal elimination half-life in adults; prolonged in overdose or renal impairment: up to 8-12 hours)
Clinical Note
moderateSulindac + Digitoxin
"Sulindac may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateSulindac + Deslanoside
"Sulindac may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateSulindac + Acetyldigitoxin
"Sulindac may decrease the cardiotoxic activities of Acetyldigitoxin."
Clinical Note
moderateSulindac + Ouabain
"Sulindac may decrease the cardiotoxic activities of Ouabain."
14 hours (sulfide active metabolite); 3-4 hours (parent sulindac). Steady-state attained in 3-4 days.
Renal: ~95% (hepatic metabolites and conjugates, <1% unchanged); biliary/fecal: ~5%
Primarily renal (about 50% as glucuronide conjugates, 25-30% as sulfide and sulfone metabolites); biliary/fecal elimination accounts for approximately 25-30%.
Category C
Category D/X
NSAID
NSAID